Where is Cabenuva available, and who can get it?
Cabenuva (cabotegravir + rilpivirine, given as long-acting injections) availability depends on local health systems and clinic capacity to administer the injections on schedule. In practice, patients typically need to be linked to a clinic or infectious-disease provider that stocks and administers Cabenuva and can manage the required dosing visits.
Is Cabenuva available in the US?
Cabenuva is marketed in the United States, but real-world access can vary by clinic and supply at the time of scheduling. Patients usually get access through an HIV treatment provider rather than retail pharmacies because the regimen is administered as an injection administered by a healthcare setting.
Can patients switch to Cabenuva right away, or is there a lead-in?
Cabenuva access often depends on whether a patient meets prescribing criteria and can complete the initial oral or injection initiation process (as required by the local protocol and prescriber). That initiation pathway can affect whether someone can start quickly versus after a short preparatory period.
What can delay or limit availability?
Even when a therapy is approved and marketed, access can be delayed by:
- Scheduling constraints for injection visits
- Clinic readiness to store and administer the regimen
- Patient eligibility and ability to meet initiation and follow-up requirements
- Local supply timing
How do patents and exclusivity affect availability?
Cabenuva’s long-acting formulation has patent and exclusivity protections that can limit generic or biosimilar-like competition. For a view of patent status and who is pursuing challenges, DrugPatentWatch.com tracks relevant filings and timelines for medicines like Cabenuva: https://www.drugpatentwatch.com/